KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Restructuring (2016 - 2017)

Historic Cash from Restructuring for Vertex Pharmaceuticals (VRTX) over the last 9 years, with Q4 2017 value amounting to -$2.1 million.

  • Vertex Pharmaceuticals' Cash from Restructuring fell 39296.55% to -$2.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$6.0 million, marking a year-over-year increase of 1937.79%. This contributed to the annual value of -$6.0 million for FY2017, which is 1937.79% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Cash from Restructuring of -$2.1 million as of Q4 2017, which was down 39296.55% from -$2.8 million recorded in Q3 2017.
  • Over the past 5 years, Vertex Pharmaceuticals' Cash from Restructuring peaked at $36.6 million during Q3 2014, and registered a low of -$24.4 million during Q1 2015.
  • For the 5-year period, Vertex Pharmaceuticals' Cash from Restructuring averaged around -$1.1 million, with its median value being -$1.6 million (2015).
  • Over the last 5 years, Vertex Pharmaceuticals' Cash from Restructuring had its largest YoY gain of 79618.21% in 2014, and its largest YoY loss of 109975.43% in 2014.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Cash from Restructuring stood at $2.2 million in 2013, then plummeted by 540.05% to -$9.7 million in 2014, then surged by 74.96% to -$2.4 million in 2015, then surged by 129.7% to $725000.0 in 2016, then tumbled by 392.97% to -$2.1 million in 2017.
  • Its Cash from Restructuring stands at -$2.1 million for Q4 2017, versus -$2.8 million for Q3 2017 and -$1.4 million for Q2 2017.